Faster recovery in patients with facial nerve palsy treated with contralateral botulinum toxin injection: a case-control study.
Abstract
[PURPOSE] Botulinum toxin (BTX, Botox) is increasingly used as an adjunct therapy to oral steroids in the management of facial paralysis, with positive outcomes. This study aimed to evaluate the additive effect of BTX injection on the non-paralyzed side and propose optimal injection timing for recovery time.
[METHODS] A total of 48 atraumatic facial paralysis patients who visited Seoul St. Mary's hospital for facial palsy between June 2015 and May 2021 were retrospectively reviewed. Patients were divided into 2 groups: the BTX injection group (BG) and the non-BTX injection group (NBG). We analyzed the recovery rate of facial palsy to H-B grade II or lower in each group, and conducted telephone surveys to collect subjective satisfaction data after BTX injection.
[RESULTS] Days of recovery to H-B grade II from symptom onset were 93.0 ± 62 and 68.7 ± 66.6 in NBG and BG, respectively. Early BTX injection (less than 17.5 days from symptom onset) was a prognostic factor for recovery to H-B grade II in less than 1 month (R = 0.935, B = 1.738, p < 0.001). Telephone survey showed subjective satisfaction in all aspects 1 month after BTX injection: function (83.3%), cosmetic (70.9%), and recovery (54.2%).
[CONCLUSION] Early contralateral facial BTX injection can shorten the recovery period of atraumatic facial palsy.
[METHODS] A total of 48 atraumatic facial paralysis patients who visited Seoul St. Mary's hospital for facial palsy between June 2015 and May 2021 were retrospectively reviewed. Patients were divided into 2 groups: the BTX injection group (BG) and the non-BTX injection group (NBG). We analyzed the recovery rate of facial palsy to H-B grade II or lower in each group, and conducted telephone surveys to collect subjective satisfaction data after BTX injection.
[RESULTS] Days of recovery to H-B grade II from symptom onset were 93.0 ± 62 and 68.7 ± 66.6 in NBG and BG, respectively. Early BTX injection (less than 17.5 days from symptom onset) was a prognostic factor for recovery to H-B grade II in less than 1 month (R = 0.935, B = 1.738, p < 0.001). Telephone survey showed subjective satisfaction in all aspects 1 month after BTX injection: function (83.3%), cosmetic (70.9%), and recovery (54.2%).
[CONCLUSION] Early contralateral facial BTX injection can shorten the recovery period of atraumatic facial palsy.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 2 | |
| 시술 | botox
|
보툴리눔독소 주사 | dict | 1 | |
| 해부 | oral steroids
|
scispacy | 1 | ||
| 약물 | steroids
|
C0038317
Steroids
|
scispacy | 1 | |
| 약물 | H-B grade II
|
scispacy | 1 | ||
| 약물 | [PURPOSE] Botulinum toxin
|
scispacy | 1 | ||
| 약물 | BTX
|
scispacy | 1 | ||
| 질환 | facial nerve palsy
|
C0015469
Facial paralysis
|
scispacy | 1 | |
| 질환 | paralysis
|
C0522224
Paralysed
|
scispacy | 1 | |
| 질환 | palsy
|
C0522224
Paralysed
|
scispacy | 1 | |
| 질환 | H-B grade II
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | facial nerve
|
scispacy | 1 | ||
| 기타 | BTX
|
scispacy | 1 | ||
| 기타 | H-B grade II
|
scispacy | 1 |
MeSH Terms
Humans; Female; Male; Middle Aged; Retrospective Studies; Facial Paralysis; Botulinum Toxins, Type A; Neuromuscular Agents; Adult; Case-Control Studies; Recovery of Function; Aged; Treatment Outcome; Injections, Intramuscular; Patient Satisfaction; Time Factors
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.